drugset / Trial / NCT03734926
A Phase 1 Study of ZSP1241 in Participants With Advanced Solid Tumors
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics, and determine the maximum tolerated dose of ZSP1241 in participants with hepatocellular carcinoma, cholangiocarcinoma, gastric cancer, esophageal cancer, colorectal cancer and other advanced solid tumors.
Timeline
- Start
- 2018-11-13
- Primary completion
- 2021-10-31
- Completion
- 2021-10-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ZSP1241 | Unknown | — | Oral |